Back to Search
Start Over
[Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines].
- Source :
-
Kardiologiia [Kardiologiia] 2020 Oct 14; Vol. 60 (9), pp. 122-133. Date of Electronic Publication: 2020 Oct 14. - Publication Year :
- 2020
-
Abstract
- Cardiovascular diseases remain a leading cause for unfavorable outcomes, including death, in patients with type 2 diabetes mellitus (DM2). In the recent decade, novel drugs, including glucagon-like peptide-1 receptor agonists (GPP-1-RA) and sodium-glucose cotransporter-2 inhibitors, have convincingly demonstrated their ability to reduce risk of cardiovascular complications in patients with DM2. This review discusses one of GPP-1-RA, semaglutide, with a special focus on the evidence-based data on its use, cardioprotective properties, and algorithms of administration consistent with current clinical recommendations.
Details
- Language :
- Russian
- ISSN :
- 0022-9040
- Volume :
- 60
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Kardiologiia
- Publication Type :
- Academic Journal
- Accession number :
- 33131483
- Full Text :
- https://doi.org/10.18087/cardio.2020.9.n1274